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Abstract
Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have
recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral
sclerosis (ALS), and may be the most common genetic cause of both neurodegenerative diseases.
Genetic variants at TMEM106B influence risk for the most common neuropathological subtype of
FTLD, characterized by inclusions of TAR DNA binding protein of 43kDa (FTLD-TDP).
Previous reports have shown that TMEM106B is a genetic modifier of FTLD-TDP caused by
progranulin (GRN) mutations, with the major (risk) allele of rs1990622 associating with earlier
age at onset of disease. Here we report that rs1990622 genotype affects age at death in a single-
site discovery cohort of FTLD patients with C9orf72 expansions (n=14), with the major allele
correlated with later age at death (p=0.024). We replicate this modifier effect in a 30-site
international neuropathological cohort of FTLD-TDP patients with C9orf72 expansions (n=75),
again finding that the major allele associates with later age at death (p=0.016), as well as later age
at onset (p=0.019). In contrast, TMEM106B genotype does not affect age at onset or death in 241
FTLD-TDP cases negative for GRN mutations or C9orf72 expansions. Thus, TMEM106B is a
genetic modifier of FTLD with C9orf72 expansions. Intriguingly, the genotype that confers
increased risk for developing FTLD-TDP (major, or T, allele of rs1990622) is associated with
later age at onset and death in C9orf72 expansion carriers, providing an example of sign epistasis
in human neurodegenerative disease.
Keywords
TMEM106B; C9orf72; frontotemporal dementia; frontotemporal lobar degeneration; amyotrophic
lateral sclerosis; genetic modifier
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is the second most common dementia in
individuals under 65 years of age [30]. The most common neuropathological subtype is
frontotemporal lobar degeneration with TAR DNA-binding protein of 43kDa (TDP-43)
inclusions (FTLD-TDP) [30]. We previously reported the minimally characterized gene,
TMEM106B, as a risk factor for FTLD-TDP by genome-wide association study (GWAS)
[38], and this association has been verified independently [12,39]. In our GWAS, three
SNPs reached genome-wide significance for association with FTLD-TDP [38]; all are
located within a 36kb haplotype block that contains TMEM106B and no other genes. The
major alleles of all three SNPs are associated with increased risk of FTLD-TDP
(p=1.08×10−11, odds ratio=1.64 for major allele of rs1990622, the top GWAS SNP) [38].
Several studies have begun to elucidate the role TMEM106B plays in FTLD-TDP.
TMEM106B levels have been shown to be increased in FTLD-TDP brains [5,38], and risk-
associated alleles resulting in amino acid variation in the TMEM106B protein have been
reported to result in higher steady-state levels of TMEM106B through slower protein
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degradation [26]. In addition, the major allele of rs1990622 has been associated with
reduced plasma progranulin (PGRN) levels in both healthy individuals and in individuals
with FTLD-TDP caused by mutations in GRN, the gene encoding progranulin [9,12].
Mutations in GRN are a major cause of familial FTLD-TDP [14], and are thought to cause
disease via haploinsufficiency of the progranulin protein [14,31]. Interestingly, among GRN
mutation carriers with FTLD (GRN(+) FTLD), TMEM106B rs1990622 major alleles have
been reported to associate with earlier age at disease onset [9]. Experiments in cell culture
systems have also demonstrated that TMEM106B and PGRN co-localize in several cell
types, including neurons, and that over-expression of TMEM106B alters intra- and
extracellular levels of PGRN [3,5,26]. Therefore, increased expression of TMEM106B may
confer risk for FTLD-TDP by altering PGRN levels.
While GRN mutations account for ~5% of clinical FTLD cases [14], and other rarer,
monogenic causes of FTLD are known (including mutations in MAPT, CHMP2B and VCP)
[17,33,41], a substantial proportion of familial cases were until recently of unknown cause.
This changed in late 2011 when two groups reported that hexanucleotide repeat expansions
in the C9orf72 gene are perhaps the most common cause of familial FTLD, familial
amyotrophic lateral sclerosis (ALS), and familial FTLD with motor neuron disease (FTLD-
MND) [11,28]. Although these mutations display an autosomal dominant mode of
inheritance, 3–6% of apparently sporadic cases of FTLD and ALS harbor C9orf72
expansions as well, which may be explained by genetic anticipation, de novo mutation, or
incomplete penetrance [11,28].
The function(s) of C9orf72 and its role in disease are currently areas of ongoing research
[10], with evidence for both loss-of-function [8,11,15,28] and gain-of-toxic-function
[1,13,25] mechanisms. At a neuropathological level, C9orf72 expansion positive FTLD
(C9orf72(+) FTLD) and ALS (C9orf72(+) ALS) cases exhibit TDP-43 pathology
reminiscent of GRN(+) FTLD, as well as mutation-negative ALS and FTLD, although
C9orf72(+) FTLD and ALS cases show unique pathological features as well [2,34,35].
Here, we assess whether TMEM106B risk genotypes exert a genetic modifier effect in
C9orf72(+) FTLD and ALS, GRN(+) FTLD, and FTLD cases without either mutation. We
also investigate whether these genotypes are associated with disease status in C9orf72(+)
FTLD and with plasma progranulin levels in C9orf72(+) expansion carriers.
METHODS
Patient cohorts
FTLD and ALS cases with C9orf72 expansions of greater than 30 hexanucleotide repeats
were identified from among cases in the Integrated Neurodegenerative Disease Database at
the University of Pennsylvania (UPenn) to form a discovery cohort [37,44]. Patients were
initially seen at the UPenn Frontotemporal Degeneration Center (FTDC), Amyotrophic
Lateral Sclerosis Center (ALSC), or Alzheimer’ s Disease Center (ADC); all were collected
with Institutional Review Board Approval. In addition to having a C9orf72 expansion, the
criteria for selection of FTLD cases was a pathological diagnosis of FTLD-TDP (n=10) or a
clinical diagnosis of FTLD or FTLD-MND (n=19), according to published criteria [16,22–
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24,27,36]. C9orf72(+) ALS cases (n=55) all met El Escorial-revised criteria [4]. Twenty of
the 55 ALS cases had autopsy confirmation of ALS pathology. For both FTLD and ALS
cases, only probands were selected. In situations where patients exhibited both dementia and
motor neuron disease (MND), cases were assigned to FTLD-MND if the initial presentation
was cognitive and to ALS if the initial presentation was MND. All C9orf72(+) FTLD and
C9orf72(+) ALS cases meeting these criteria were included without bias for familial-vs.-
apparently-sporadic patterns of inheritance, and without prior knowledge of TMEM106B
genotype.
The C9orf72(+) FTLD discovery cohort is 93.5% white (6.5% unknown ethnicity) and
54.8% male. The C9orf72(+) ALS cohort is 87.2% white, 5.6% black, 3.5% Latino, and
3.7% unknown ethnicity with 59.8% males. Age at onset and age at death were collected,
but both were not available on all subjects (e.g. no age at death for living subjects, and
sometimes no known age at onset for autopsy cases), therefore the numbers of cases from
each cohort vary depending on the data needed for analysis. For the discovery cohort, age at
onset was defined as the age at initial complaint, based on review of medical records.
The previously published and publicly available FTLD-TDP GWAS from the International
Collaboration for Frontotemporal Lobar Degeneration was used as a replication cohort [38].
As previously described [38], all cases of this postmortem cohort were self-described as
White, of European ancestry. In addition, samples were screened by principle components
analysis of genomewide genotyping data, and at >200 ancestry informative markers, to
reduce effects of population stratification. Only those cases with >90% inferred CEU (based
on HapMap CEU population of Utah residents with ancestry from Northern and Western
Europe) ancestry were included in the original GWAS [38], from which all cases of the
current replication cohort are derived.
A subset of the FTLD-TDP cases were known from the original study to have a pathogenic
GRN mutation (n=116) and are used here as a comparison group [7,38]. The majority of
cases lacking a GRN or VCP mutation (n=321) were screened for C9orf72 expansions either
by the contributing site or by UPenn, using published methods [11,28]. 80 FTLD-TDP cases
with C9orf72 expansions were identified from 30 clinical sites that agreed to collaborate on
this project (see Acknowledgement section for a full listing of clinical sites). Of the 80
cases, 5 UPenn cases overlapped with the UPenn discovery cohort and were removed,
leaving 75 C9orf72 expansion cases for analysis in the replication cohort. In addition, 241
cases were formally tested for (and found negative for) C9orf72 expansions, and these were
used as the mutation-negative FTLD-TDP cohort. We note that there were additional
C9orf72(+) FTLD-TDP cases in the GWAS, but only those cases from sites agreeing to
collaborate on this study (constituting >80% of the total FTLD-TDP GWAS C9orf72(+)
cases) are included here.
For the replication cohort, age at onset and age at death were provided by the contributing
clinical site.
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Genotyping
DNA from UPenn cases, extracted from blood or brain samples as previously described
[38], was tested for rs1990622 genotype using one of two methods: TaqMan chemistry-
based allelic discrimination assays as previously described [5,38], or a custom Sequenom
MassArray genotyping panel that includes PCR and extension primers for rs1990622. PCR
and extension primer sequences for the Sequenom panel are available on request. Both
genotyping methods were compared and found to be concordant (data not shown) [37].
Plasma progranulin measurement
Plasma samples were collected from UPenn ALS and FTLD discovery cohort patients,
aliquotted, and stored at −80°C as previously described [6]. Progranulin levels were
measured using a commercially available sandwich ELISA (Human progranulin ELISA kit,
AdipoGen), according to manufacturer instructions.
Statistical analyses
Linear regression analyses evaluating the association of TMEM106B genotype with age at
death or age at disease onset were performed in R, with or without covariates as described in
the text. Two-tailed p-values are reported for the discovery cohort, and one-tailed p-values
are reported for the FTLD-TDP GWAS replication cohort, since the expected directionality
was known. For the combined dataset, survival analyses (Kaplan-Meier method) were also
performed in Prism, and two-tailed p-values from the log-rank test for trend are reported.
Where indicated, codominant, major-allele-dominant, and minor-allele dominant models of
genetic effect were investigated.
In addition, we tested for association between TMEM106B genotype and disease for
genetically-defined subsets of FTLD (C9orf72(+) FTLD, GRN(+) FTLD, or individuals
without C9orf72 expansions or GRN mutations). Chi-square statistics were calculated for
rs1990622 using the FTLD-TDP GWAS cases and controls [38].
For plasma progranulin analyses, Kruskal-Wallis tests were used to compare plasma
progranulin measures among carriers of different TMEM106B genotypes under a
codominant model, and Mann-Whitney tests were used to compare different TMEM106B
genotypes under major-allele-dominant and minor-allele dominant models. In addition,
multivariate linear regressions predicting plasma progranulin levels from TMEM106B
genotype were used to adjust for sex, age, duration of disease, or clinical manifestation as
described in the text.
R-scripts for analyses are available upon request.
RESULTS
TMEM106B genotype at rs1990622 influences age at death in a discovery cohort of
C9orf72(+) FTLD
TMEM106B genotype has been shown to demonstrate a genetic modifier effect in FTLD-
TDP caused by autosomal dominant mutations in the progranulin gene (GRN) [9]. We
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therefore asked whether genetic variation at TMEM106B influences age at death or age at
onset in C9orf72(+) FTLD or ALS disease cases. We assumed a codominant model for
these initial analyses.
In C9orf72(+) FTLD (n=14), age at death was significantly correlated with TMEM106B
genotype at rs1990622, the SNP previously found in our GWAS to associate most strongly
with FTLD-TDP risk (p=0.024, Table 1). Adjusting for sex and presence/absence of co-
existing MND did not affect this association. Moreover, the direction of association was
surprising; specifically, the major allele of rs1990622 (C) was associated with later age at
death in C9orf72(+) FTLD. In our GWAS, the major allele of rs1990622 was found to be
associated with increased risk for the development of FTLD.
In contrast, rs1990622 genotype did not affect age at death in C9orf72(+) ALS (n=39, Table
1). In this discovery cohort, rs1990622 genotype did not affect age at onset for C9orf72
expansion carriers who presented with either ALS (n=47) or FTLD (n=26). However, a
statistically significant association emerged when we performed a multivariate analysis
controlling for gender and presence of FTD in the clinical ALS cases, with the major allele
associating with earlier age at onset (n=47, Table 1).
TMEM106B genotype at rs1990622 influences age at onset and age at death in a replication
cohort of C9orf72(+) FTLD
We sought to replicate the genetic modifier effect of TMEM106B in C9orf72(+) FTLD in an
independent cohort of patients. Since the majority of cases from our GWAS had been
screened for the presence of C9orf72 expansions, these cases provided an ideal replication
cohort to evaluate the effect of TMEM106B rs1990622 genotype on age at death in
C9orf72(+) FTLD for three key reasons. First, since the FTLD-TDP GWAS predated the
discovery of C9orf72 expansions as a cause of FTLD, this large, international cohort was
unbiased in enrollment with respect to C9orf72 status. Second, all cases were
neuropathologically confirmed to have FTLD-TDP, ensuring neuropathological
homogeneity. Third, because all cases had undergone genome-wide genotyping and filtering
for effects from population stratification, we could be certain that effects from cryptic
familial relationships or population stratification would be minimal.
As shown in Table 2, rs1990622 genotype was again correlated with age at death in this
cohort (n=75), in both univariate analyses (p=0.016) and linear regression models adjusting
for sex and the presence or absence of MND (p=0.019). Moreover, in this larger replication
cohort, rs1990622 genotype was also correlated with age at onset (n=68 with age at onset
data, p=0.019 for univariate analyses and p=0.032 for multivariate analyses adjusting for sex
and presence or absence of MND). Consistent with the results from our discovery cohort,
the major allele (T) of rs1990622 was associated with later age at death, as well as later age
at onset. Indeed, patients showed later disease onset and later death by more than three years
for each additional major allele at rs1990622 carried.
We further examined this genetic modifier effect using Kaplan-Meier survival analyses
performed on the combined cohort (discovery plus replication, n=89 for age at death
analysis, n=94 for age at onset analysis) of C9orf72(+) FTLD cases. As shown in Fig. 1,
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TMEM106B genotypes at rs1990622 were significantly associated with age at death (Fig.
1A, p=0.046, log rank test for trend), with a trend towards association for age at onset (Fig.
1C, p=0.064) in this combined cohort. In addition, we observed that the curve separation
between rs1990622 minor allele homozygotes (CC) and heterozygotes (TC) was greater than
the separation between heterozygotes (TC) and major allele homozygotes (TT). We
therefore re-analyzed our data under a major-allele dominant model for rs1990622 and
observed a stronger effect of TMEM106B genotype on age at death (p=0.041, log rank test
for trend) and age at onset (p=0.037, log rank test for trend) in C9orf72(+) FTLD. Indeed, at
any given age, minor allele (C) homozygotes at rs1990622 had more than twice the risk of
manifesting disease (Fig. 1D, HR 2.022, 95% CI 1.042–3.925), and more than twice the risk
of death (Fig. 1B, HR 2.039, 95% CI 1.031–4.033), compared to other genotypes.
TMEM106B genotype does not exert a genetic modifier effect in C9orf72 expansion
negative FTLD-TDP cases
We next asked whether the TMEM106B genetic modifier effect observed for C9orf72(+)
FTLD extended to FTLD-TDP cases without C9orf72 expansions, again using FTLD-TDP
cases from the FTLD-TDP GWAS for which C9orf72 and/or GRN mutation status was
known. We considered cases with and without GRN mutations separately.
As shown in Fig. 2A, TMEM106B rs1990622 genotype did not affect age at death in FTLD-
TDP cases without C9orf72 expansions or GRN mutations (n=241). In the subset of GRN-
related FTLD-TDP (n=116, Fig. 2B), only one rs1990622 CC individual had age at death
information available, so we could only compare TT and TC individuals, who did not differ
significantly in age at death. Similar results were obtained for age-at-onset analyses (data
not shown).
TMEM106B genotype is associated with FTLD-TDP in C9orf72 expansion carriers
The observed genetic modifier effect for TMEM106B in C9orf72(+) FTLD is surprising in
its direction. Specifically, the rs1990622 major allele associated with increased risk of
FTLD-TDP by GWAS is correlated with older age at onset and death among C9orf72(+)
FTLD cases, implying a beneficial effect in this mutation subgroup. We therefore examined
TMEM106B rs1990622 allele frequencies in 116 GRN(+) FTLD cases, 80 C9orf72(+)
FTLD cases, and 241 FTLD-TDP cases in which mutations in GRN and expansions in
C9orf72 had been excluded. As with the age-at-onset and age-at-death analyses, FTLD-TDP
cases were from our prior FTLD-TDP GWAS, although numbers in each group are slightly
higher because individuals with genotypes but lacking age-at-death or age-at-onset data
could be included. As shown in Table 3, TMEM106B rs1990622 genotype was significantly
associated with FTLD-TDP in all three subgroups, with the same direction of association in
all three subgroups. In each case, the major allele of rs1990622 was enriched in disease.
TMEM106B genotype is not associated with plasma progranulin levels in C9orf72
expansion carriers
TMEM106B genotype has been reported to influence plasma progranulin levels in healthy
individuals and GRN+ FTLD, with the rs1990622 major allele associated with decreased
progranulin expression. We evaluated whether this relationship was also true in C9orf72
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expansion carriers. In a convenience subset of 24 C9orf72 expansion carriers (20 with
C9orf72(+) ALS and 4 with C9orf72(+) FTLD) from the UPenn discovery cohort for whom
we had plasma samples, we measured progranulin levels using an enzyme-linked
immunosorbent assay (ELISA). As shown in Fig. 2C, there were no significant differences
in plasma progranulin levels comparing C9orf72 expansion carriers with TT, TC, and CC
genotypes at rs1990622. Adjusting for sex and age at plasma sampling or duration of disease
did not affect this result. Additionally adjusting for clinical manifestation as FTLD or ALS
did not affect this result.
DISCUSSION
In the current study, we find that TMEM106B is a genetic modifier for C9orf72(+) FTLD,
demonstrating a significantly later age at death and age at onset for TMEM106B rs1990622
major allele (T) carriers. This effect appears to be specific to C9orf72(+) FTLD, since
C9orf72(−)FTLD cases do not differ in age at death depending on rs1990622 genotype. In
addition, rs1990622 major allele carriers are significantly enriched in C9orf72(+) FTLD,
compared to neurologically normal controls. Finally, among C9orf72 expansion carriers, we
do not see a clear effect of rs1990622 genotype on plasma progranulin levels.
We observe that TMEM106B genotypes exert a genetic modifier effect in C9orf72(+)
FTLD. Examples of common risk variants acting as genetic modifiers in Mendelian
subgroups of disease are increasingly being described. In the field of neurodegeneration, one
well-known example is the age-at-onset modifying effect of Apolipoprotein E (APOE)
isoform in PSEN2-related-Alzheimer’ s Disease [43]. Moreover, in GRN+ FTLD,
TMEM106B has been reported as a genetic modifier affecting both age-at-onset and
circulating levels of progranulin [9,12].
What is more unusual in this case is the direction of the genetic modifier effect. Specifically,
the TMEM106B allele that is associated with increased risk of developing FTLD-TDP [38]
(and earlier age at onset in GRN+ FTLD [9]) appears to ameliorate the disease phenotype
(associating with later age at death and onset) in C9orf72(+) FTLD. This effect may be an
example of the general phenomenon of sign epistasis, in which a genetic variant is beneficial
on some genetic backgrounds but deleterious in others. In this case, the genetic variant in
question is TMEM106B genotype at rs1990622 (and linked SNPs), and the genetic
backgrounds demonstrating opposing effects are (1) C9orf72(+) individuals -- where the
major allele at rs1990622 and linked SNPs is protective in modulating the severity of FTLD
manifestation, as demonstrated by older age at onset and age at death and (2) C9orf72(−)
individuals -- where the major allele at rs1990622 and linked SNPs is harmful in conferring
increased risk of developing FTLD.
Sign epistasis has its conceptual underpinnings in the evolutionary biology literature [42].
With the advent of modern experimental tools, sign epistasis has been demonstrated in lower
organisms such as bacteria [32], with reports for this phenomenon in the realm of human
genetics and human disease genetics as well [18,19]. In the few reported empirically-derived
examples of sign epistasis, the two (or more) genetic loci involved converge mechanistically
in, for example, antibiotic resistance pathways [29] or enzyme-substrate interactions [45].
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Thus, the observed epistasis between TMEM106B and C9orf72 suggests that these two
proteins may have convergent functions in the pathophysiology of FTLD-TDP. Intriguingly,
TMEM106B has been linked to endosomal-lysosomal pathways [3,5,20,26]. The largely
uncharacterized protein C9orf72 is structurally related to DENN protein family members
[21]. DENN proteins function in the regulation of Rab GTPases, which in turn regulate the
many membrane trafficking events needed for proper function of the endosomal-lysosomal
pathway.
We note that TMEM106B rs1990622 genotypes differ in allelic frequencies between
C9orf72(+) FTLD-TDP and normal controls; this situation in which a common variant
shows allelic association with disease even in a monogenic, highly-penetrant subgroup of
disease has been reported in GRN+ FTLD-TDP as well [12,38]. In the case of the GRN
mutants, a potential explanation may lie in ascertainment bias, since TMEM106B risk
variant carriers may manifest disease at an earlier age [9], making it more likely for them to
be included in a cross-sectional sampling of diseased individuals. Alternately, the protective
effect of the modifier locus (e.g. TMEM106B) may be significant enough to counter-act the
disease-causing effects of the Mendelian genetic cause (e.g. GRN), such that carriers of
protective variants never manifest clinically despite possessing a highly-penetrant genetic
mutation. Such an argument cannot explain our current result, however, since the rs1990622
major allele (found by genome-wide association to be enriched in FTLD-TDP) appears to
delay age at death and age at onset in C9orf72(+) FTLD cases. An alternate explanation
may lie in the fact that C9orf72 expansions have a broad range of phenotypic expression,
manifesting as ALS, FTLD, or a syndrome combining both motor neuron disease and
dementia. We have previously shown that ALS patients who are major allele carriers at
rs1990622 are more likely to demonstrate cognitive impairment [40]. Thus, it is possible that
TMEM106B genotype modulates the phenotypic expression of C9orf72 expansions, with
rs1990622 major allele carriers more likely to manifest clinically with dementia. Whether an
effect of directing regional pathology towards cognitive regions rather than motor regions
also underlies the apparently protective effect on age at death for TMEM106B rs1990622
major allele carriers with C9orf72 expansions remains to be seen.
It is notable that we were able to replicate the genetic modifier effect of TMEM106B
genotype in C9orf72(+) FTLD in a 30-site, international cohort of subjects. Undoubtedly,
site-to-site variation in methods of ascertaining age at onset would contribute to noise, and
site-to-site variation in practice with respect to aggressiveness of clinical care with a fatal
neurodegenerative disease would contribute to differences in age at death in such a dataset.
The ability to see a significant genetic modifier effect of TMEM106B on C9orf72 in such a
cohort, nonetheless, may have been helped by the fact that our replication cohort was
homogeneous with respect to neuropathology (all FTLD-TDP), and genome-wide
genotyping in these individuals allowed us to exclude important potential sources of noise,
such as population stratification and cryptic familial relationships among individuals. In any
case, the international, multi-site nature of our replication cohort increases our confidence
that our findings are not due to artifact.
The current study has several limitations. First, while we did not see an age-at-death-
modifying effect for TMEM106B in C9orf72 expansion-associated ALS, our sample size
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was small (n=39) and likely underpowered to adequately address this question. Thus, future
studies examining this relationship in more C9orf72-expansion-related ALS cases would be
a valuable addition to the data presented here. Second, we did not see a clear modifier effect
of TMEM106B genotype in the GRN(+) FTLD-TDP cases in this study, as has been
previously reported [9]. However, our study had only one rs1990622 minor allele
homozygote in the GRN+ FTLD subgroup, precluding our ability to examine TMEM106B
genotype effect in a major-allele-dominant model. Third, we were able to obtain plasma
samples on 24 C9orf72 expansion carriers, in whom we measured progranulin levels.
Plasma progranulin levels did not differ by TMEM106B genotype in this set of samples,
which could reflect either insufficient sample size or a biologically-relevant finding. Should
further studies in larger sample sizes corroborate our result, this would suggest that C9orf72
expansions may interrupt the means by which TMEM106B affects circulating progranulin
levels. Finally, our study was a targeted evaluation of one locus (TMEM106B) for genetic
modifier effect in C9orf72 expansion carriers, rather than a comprehensive screen for
genetic modifiers in C9orf72(+) FTLD or ALS. It is entirely possible that other loci with
epistatic effects exist and also play an important role in modulating the phenotype associated
with C9orf72 expansions. In conclusion, we demonstrate here that TMEM106B is the first
reported genetic modifier in C9orf72 expansion-related FTLD. Our findings suggest a
previously unsuspected link between these two proteins in the pathophysiology of FTLD
and open up new directions for the development of disease-modifying therapy
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(GWAS); this GWAS led to the discovery that common variants in TMEM106B are a
genetic risk factor for FTLD-TDP [38]. Members of the Collaboration who contributed
C9orf72(+)FTLD-TDP cases for the current study include Irina Alafuzoff, Anna Antonell,
Nenad Bogdanovic, William Brooks, Nigel Cairns, Johnathan Cooper-Knock, Carl W.
Cotman, Patrick Cras, Marc Cruts, Peter P. De Deyn, Charles DeCarli, Carol Dobson-Stone,
Sebastiaan Engelborghs, Nick Fox, Douglas Galasko, Marla Gearing, Ilse Gijselinck, Jordan
Grafman, Paivi Hartikainen, Kimmo J. Hatanpaa, J. Robin Highley, John Hodges, Christine
Hulette, Paul G. Ince, Lee-Way Jin, Janine Kirby, Julia Kofler, Jillian Kril, John J. B. Kwok,
Allan Levey, Andrew Lieberman, Albert Llado, Jean-Jacques Martin, Eliezer Masliah,
Christopher J. McDermott, Catriona McLean, Ann C. McKee, Simon Mead, Carol A.
Miller, Josh Miller, David Munoz, Jill Murrell, Henry Paulson, Olivier Piguet, Martin
Rossor, Raquel Sanchez-Valle, Mary Sano, Julie Schneider, Lisa Silbert, Salvatore Spina,
Julie van der Zee, Tim Van Langenhove, Jason Warren, Stephen B. Wharton, Charles L.
White III, Randall Woltjer.
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Fig. 1. TMEM106B genotype influences age at death and age at onset in C9orf72(+) FTLD
All survival analyses were performed in 104 total C9orf72(+) FTLD cases, from the combined discovery and replication
cohorts. Of these 104 total cases, 89 had available age-at-death data, and 94 had age-at-onset data.
A) Age at death was significantly associated with TMEM106B genotype at rs1990622, the top SNP associated with FTLD-TDP
in our prior GWAS. Log rank test for trend two-tailed p=0.046, assuming a codominant model.
B) Under a major-allele-dominant model, TMEM106B rs1990622 genotype was even more significantly associated with age at
death, with more than twice the risk of death at any given age for CC carriers compared to carriers of one or more T alleles (two-
tailed p=0.041, HR=2.039, 95% CI 1.031–4.033).
C) Age at onset showed a trend towards association with TMEM106B genotype at rs1990622. Log rank test for trend two-tailed
p=0.064, assuming a codominant model.
D) Under a major-allele-dominant model, TMEM106B rs1990622 genotype showed a significant association with age at disease
onset, with more than twice the risk of disease onset at any given age for CC carriers compared to carriers of one or more T
alleles (two-tailed p=0.037, HR=2.022, 95% CI 1.042–3.925)
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Fig. 2. TMEM106B genotype does not affect age at death or age at onset for FTLD-TDP without C9orf72 expansions
A) In 241 FTLD-TDP cases negative for GRN mutations or C9orf72 expansions, TMEM106B genotype at rs1990622 did not
affect age at death.
B) In 116 FTLD-TDP cases with GRN mutations, we found no significant difference in age at death comparing TT and TC
carriers at rs1990622. In this cohort, only one individual had the CC genotype, precluding our ability to evaluate the influence of
this genotype.
C) Plasma progranulin levels were measured in a convenience subset of 24 C9orf72 expansion carriers by ELISA. Progranulin
levels did not differ significantly by TMEM106B rs1990622 genotype, although the TT carriers exhibited significantly less
variance in their progranulin levels. Black dots indicate individuals who presented with ALS, while red dots indicate individuals
who presented with FTLD.
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Table 1
TMEM106B genotype affects age at death in C9orf72 expansion carriers with FTLD or FTLD-TDP in a discovery cohort
Linear regressions were used to evaluate the effect of TMEM106B genotype at rs1990622 on the age at death or age at onset in C9orf72 expansion
carriers from a discovery cohort. In individuals who presented with clinical FTLD or FTLD-TDP, rs1990622 genotype was significantly associated with
age at death in both univariate models and models adjusting for age and presence/absence of motor neuron disease (MND). In individuals who presented
with ALS, rs1990622 genotype was not significantly associated with age at death, with a trend towards association with age at onset. Asterisks denote
significance.
Disease Outcome Predictors Beta (rs1990622, each major allele) R2 for model P-value (rs1990622)
FTLD and FTLD-TDP Age at Death (n=14) rs1990622 +6.278 0.303 0.024 *
rs1990622, Sex, MND +5.297 0.393 0.049 *
Age at Onset (n=26) rs1990622 n.s.
rs1990622, Sex, MND n.s.
ALS Age at Death (n=39) rs1990622 n.s.
rs1990622, Sex, FTD n.s.
Age at Onset (n=47) rs1990622 −4.264 0.044 0.085 n.s.
rs1990622, Sex, FTD −4.900 0.075 0.048 *
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Table 2
TMEM106B genotype affects age at death and age at onset in C9orf72 expansion carriers in a multi-site FTLD-TDP replication cohort
Linear regressions were used to evaluate the effect of TMEM106B genotype at rs1990622 on the age at death or age at onset in C9orf72(+) FTLD from a
multi-site replication cohort of FTLD-TDP cases. rs1990622 genotype was significantly associated with both age at death and age at onset, in both
univariate models and models adjusting for age and presence/absence of motor neuron disease (MND). Asterisks denote significance.
Disease Outcome Predictors Beta (rs1990622, each major allele) R2 for model P-value (rs1990622)
FTLD-TDP Age at Death (n=75) rs1990622 +3.342 0.048 0.016 *
rs1990622, Sex, MND +3.413 0.032 0.019 *
Age at Onset (n=68) rs1990622 +3.473 0.049 0.019 *
rs1990622, Sex, MND +3.198 0.057 0.032 *
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Table 3
TMEM106B rs1990622 genotype is associated with FTLD-TDP in all genetic subgroups
Chi-square tests were performed to evaluate for association between disease and rs1990622 genotype for FTLD-TDP subgroups defined by the presence
of GRN mutations (GRN(+) FTLD-TDP), presence of C9orf72 expansions (C9orf72(+) FTLD-TDP), or the absence of both genetic mutations (FTLD-
TDP (no mutation)). The major allele was significantly associated with disease in all three subgroups. Allele frequencies for normal controls provided
here are from our previously published GWAS.
Disease status N rs1990622 Major allele T rs1990622 Minor allele C p-value Odds ratio 95% CI
Normal 2509 0.564 0.436 -
GRN(+) FTLD-TDP 116 0.776 0.224 <0.0001 2.675 1.955–3.660
C9orf72(+)FTLD-TDP 80 0.669 0.331 0.008 1.560 1.117–2.179
FTLD-TDP (no mutation) 241 0.640 0.360 0.001 1.375 1.131–1.671
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